MILabs

Clarity that advances discovery

MILabs empowers researchers to see biology with depth and confidence, producing reliable, reproducible insight that strengthens scientific discovery and drives real-world impact.

With decades of scientific leadership and a track record of high-resolution innovation, MILabs helps teams visualize meaningful signals, quantify complex biological processes, and generate evidence that holds up across studies. Through flexible molecular and anatomical imaging configurations, a streamlined workflow, and close scientific partnership, MILabs reduces complexity while supporting stronger outcomes.

See biological processes with greater clarity and confidence

Thanks to MILabs’ high-resolution imaging solutions, researchers can visualize tracer behavior, quantify signals, and generate reliable, reproducible insight across diverse research areas.

Clearer insight with less friction

MILabs brings molecular and anatomical imaging together in a scalable workflow, so researchers can build the configuration they need today and evolve it as new questions emerge. A unified software experience helps teams capture and reconstruct data consistently across modalities, reducing variability, simplifying training, and supporting reliable, reproducible outcomes across studies.

Imaging for a wide range of study designs

Whether you’re exploring neurobiology, oncology, cardiovascular systems, tracer development, or emerging research areas, MILabs helps you generate the evidence you need with clarity and reproducibility. Flexible imaging configurations and unified workflows support a wide range of study designs, helping research teams work efficiently and build stronger conclusions.

Hear from the experts

Resources

See how researchers worldwide use MILabs imaging to validate findings and advance scientific understanding. Explore peer-reviewed studies, technical articles, white papers, and real-world examples that highlight what MILabs systems make possible across research disciplines.

Peer-to-peer expert partnerships

Count on support from trained application and service specialists who minimize downtime and enable researchers to keep their studies running efficiently and on schedule through personal, cross-disciplinary collaboration.

Upcoming events

Connect with the MILabs team at leading scientific conferences, workshops, and industry events.

No events found.
No events found.

News & Updates

Explore announcements, customer stories, technology updates, and highlights from the scientific community.

Frost & Sullivan Product Innovation Award for VECTor

The Frost & Sullivan Best Practices team has presented MILabs with the 2010 New Product Innovation Award for VECTor. In their analysis MILabs is recognized as a rapidly growing company standing out among the players in the Preclinical Imaging market with world-class products. MILabs’ proprietary VECTor technology provides fully integrated simultaneous SPECT and PET imaging with sub-mm resolution. In numerous molecular imaging applications VECTor surpasses the resolution capabilities of both classical coincidence PET and competing SPECT technologies.

Press release: TU Delft and MILabs merge PET and SPECT biomedical imaging techniques

TU Delft and MILabs merge PET and SPECT biomedical imaging techniques and deliver increased resolution TU Delft and Molecular Imaging Labs (MILabs) have succeeded in combining two forms of medical imaging techniques into one piece of equipment. These techniques are particularly useful for cancer research. The two techniques are known as microPET and microSPECT. SPECT and PET can be performed simultaneously and they give a higher resolution than traditional microSPECT and microPET. The new device is known as the VECTor (Versatile Emission Computed Tomography) and is designed for use in fundamental research into the functioning of cells and organs. It can show functional details smaller than half a millimetre.

Study shows: SPECT and PET are useful in imaging IGF-1R

Dutch researchers using preclinical imagers U-SPECT from MILabs of Utrecht, The Netherlands, and Inveon PET from Siemens Healthcare of Knoxville TN, said the imaging methods allowed them to successfully and noninvasively visualize the insulinlike growth factor 1 receptor among animal subjects with triple-negative breast cancer. Being able to image the receptor could improve patient selection from the triple-negative breast cancer patient population for targeted treatment using IGF-1R antibodies, an expert said. For more information see the Full article at AuntMinnie.com (free registration)
No results found.